Although the IDSA makes no recornrn

Although the IDSA makes no recornrnendations specific to the treatment of NF in children, the combination of clindamycin and a third-generation cephalosporin or monotherapy with a ß-lactam/ß-lactarnase combination are reasonable empiric regimens that would cover both monomicrobial and polymicrobial NF (Reference 15). Additional gram-negative and anaerobic coverage may be required in children at risk of polymicrobial NF because of underlying medical conditions and immunocompromised states. When antimicrobial options are limited because of pathogen susceptibility and need for tissue penetration, the benefit of fluoroquinolone use in children is believed to outweigh the minimal risks of musculoskeletal adverse effects, which is endorsed by the American Academy of Pediatrics (AAP)